Skip to main content

Featured

Property sales dip 27.5%

The Land Registry recorded 3,189 sale and purchase agreements for all building units received for registration in February, down 27.5% compared with January and 46.7% lower year-on-year.   The total consideration for such agreements in February fell 32.9% from January, to $22.6 billion, while a 48.5% year-on-year decrease was recorded.   Of the agreements, 2,375 were for residential units, down 31.7% from January and 44.5% lower than a year ago.   The total consideration for residential units was $19.1 billion, a decrease of 31.3% compared with January and down 47.9% year-on-year.   There were 276,910 land register searches last month. http://dlvr.it/T3ZqYl

Vaccine protection under scrutiny

Secretary for Food & Health Prof Sophia Chan said experts of the Joint Scientific Committee under the Centre for Health Protection will monitor the situation of new COVID-19 variants and review the data on the protection of various vaccines against such variants.   Speaking to the media after attending a radio programme today, Prof Chan noted that the committee has given information about the protection of different vaccines against the new variants.   She said: “According to the experts, the BioNtech vaccine is able to protect against some of the variants of concern. For the Sinovac vaccine, they are still waiting for further information from Sinovac.   “The experts will continue to monitor the situation and review any data provided to the Department of Health.”   For the vaccine produced by AstraZeneca, which the Government has signed an advance purchase agreement with, Prof Chan said the Government is aware of the news reports concerning the vaccine in different countries.   “We also notice there is news from the World Health Organization and also some countries most recently said that all the adverse effects are not related to or do not have a direct relationship with the vaccination of the AstraZeneca vaccine.   “We will continue to monitor the situation and the Department of Health has asked the manufacturer for further information.”   She explained that regarding the procedure, the manufacturer must first apply for approval for use in Hong Kong and the Advisory Panel on COVID-19 Vaccines will review the data before it recommends it for authorisation by the Government.   Such a process has not yet started, Prof Chan added.
http://dlvr.it/Rw1Hth

Popular Posts